Vernon Bernardino
Vernon Bernardino is an analyst in Seaport Global Securities' life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including FBR & Co., Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.
Recent Quotes
"ATNM was granted SME status, which provides assistance and financial support, as well as compelling commercial opportunities in the EU."
—
Vernon Bernardino, FBR & Co.
(8/9/16)
more >
"ATNM's focus on antibodies linked to radioactive payloads is underappreciated."
—
Vernon Bernardino, FBR & Co.
(6/29/16)
more >
"IMNP's b-mab could provide significant advantages over standard treatment for bullous pemphigoid."
—
Vernon Bernardino, FBR & Co.
(6/14/16)
more >
"IMNP's bertilimumab could play an important role in challenging inflammatory diseases."
—
Vernon Bernardino, FBR & Co.
(6/8/16)
more >
"IMNP is making meaningful progress advancing its portfolio of immuno-inflammation and immuno-oncology product candidates."
—
Vernon Bernardino, FBR & Co.
(5/20/16)
more >
"Based on encouraging preclinical datar, we think RNN's Supinoxin could become validated as a treatment for solid tumors."
—
Vernon Bernardino, FBR & Co.
(5/10/16)
more >
"We expect momentum for ATNM's Iomab-B to accelerate in mid-2016."
—
Vernon Bernardino, FBR & Co.
(4/29/16)
more >
"Securing funds from institutional investors is a strong vote of confidence in IMNP's ability to achieve near-term catalysts."
—
Vernon Bernardino, MLV & Co
(4/8/16)
more >
